Q2 Earnings: Regeneron and Cigna Outperform Expectations
- August 03rd, 2023
- 353 views
Shares of Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) surged over 5% in pre-market trading following an impressive second quarter 2023 earnings report. The company exceeded expectations, reporting adjusted earnings per share (EPS) of $10.24 and revenues of $3.16 billion, surpassing the consensus estimates of $9.84 on revenues of $3.01 billion.
In pre-market, $REGN was trading at $778.10, reflecting a gain of $45.98 (+6.28%).
In a separate development, The Cigna Group (NYSE: CI) unveiled its Q2 2023 financial results, with adjusted EPS of $6.13 and revenues of $48.62 billion, outperforming the consensus estimate of $6.02 on revenue of $47.31 billion.
Looking ahead, the company provided an optimistic outlook for full-year 2023 adjusted EPS, targeting at least $24.70, surpassing the consensus projection of $24.69.
$CI was trading at $299.80 in pre-market, up $0.40 (+0.13%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Countdown to Earnings: Qualcomm, McKesson, and Humana Take the Stage
November 03rd, 2025Earnings Preview: DoorDash, Cencora, and Fortinet in Focus
November 03rd, 2025Wall Street Eyes Palantir, Diamondback, and Hologic Ahead of Earnings
November 02nd, 2025Crown Equity Holdings, Inc. Announces Dissolution of Partnership with Herbal Works Inc.
November 02nd, 2025Cadence Design Systems, Celestica, and F5 Earnings Preview
October 26th, 2025
Member Login